Inhibition of vesicular uptake of monoamines by hyperforin

Life Sciences

Volumn 71, Issue 19, 2002, Pages 2227-2237

  Roz, Netta ^a   Mazur, Yehuda ^b   Hirshfeld, Amiram ^b   Rehavi, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Dopamine; Hyperforin; Hypericum perforatum; Norepinephrine; Serotonin; Vesicular monoamine transporter

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DESIPRAMINE; DIHYDROTETRABENAZINE; DOPAMINE; FLUOXETINE; HYPERFORIN; MONOAMINE; NEUROTRANSMITTER; NISOXETINE; NORADRENALIN; PAROXETINE; SEROTONIN; VANOXERINE;

ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CYTOPLASM; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; DRUG SELECTIVITY; DRUG UPTAKE; FOREBRAIN; NEUROTRANSMITTER RELEASE; NONHUMAN; SODIUM TRANSPORT; SYNAPTIC MEMBRANE;

ANIMAL; ANTIBIOTICS; BIOGENIC MONOAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; HYPERICUM; MALE; NEUROTRANSMITTER UPTAKE INHIBITORS; PIPERAZINES; PLANT EXTRACTS; PROSENCEPHALON; RATS; SYNAPTOSOMES; TERPENES;

HYPERICUM PERFORATUM;

EID: 0037183747     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)01995-1     Document Type: Article

References (39)

1. Miller N.D. St. John's wort (Hypericum perforatum): clinical effects on depression and other conditions. Alternative medicine review. 3:1998;18-26.
2. Ernst E. St. John's wort, an antidepressant? A systematic criteria-based review. Phytomedicine. 2:1995;67-71.
3. Linde K., Ramirez G., Mulrow C.D., Pauls A., Weidenhammer W., Melchart D. St. John's wort for depression - an overview and meta-analysis of randomized clinical trials. British Medical Journal. 313:1996;253-258.
4. Volz H.P. Controlled clinical trials of Hypericum extracts in depressed patients - an overview. Pharmacopsychiatry. 30(Suppl. 2):1997;72-76.
5. Bhattacharya S.K., Chakrabarti A., Chatterjee S.S. Activity profiles of two Hyperforin-containing Hypericum extracts in behavioral models. Pharmacopsychiatry. 31(Suppl. 1):1998;22-29.
6. Butterweck V., Petereit F., Winterhoff H., Nahrstedt A. Solubilized Hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Medica. 64:1998;291-294.
7. Panocka I., Perfumi M., Angeletti S., Ciccocioppo R., Massi M. Effects of Hypericum perforatum extract on ethanol intake, and on behavioral despair: a search for the neurochemical systems involved. Pharmacology Biochemistry and Behavior. 66:2000;105-111.
8. Harrer G., Schulz V. Clinical investigation of the antidepressant effectiveness of hypericum. Journal of Geriatric Psychiatry and Neurology. 7(Suppl. 1):1994;S6-S8.
9. Di-Carlo G., Borrelli F., Ernst E., Izzo A.A. St. John's wort: prozac from the plant kingdom. Trends in Pharmacological Sciences. 22:2001;292-297.
10. Wheatley D. LI160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6 week clinical trial. Pharmacopsychiatry. 30(Suppl. 2):1997;77-80.
11. Suzuki O., Katsumata Y., Oya M., Bladt S., Wagner H. Inhibition of monoamine oxidase by hypericin. Planta Medica. 50:1984;272-274.
12. Cott J.M. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry. 30(Suppl. 2):1997;108-112.
13. Müller W.E., Kasper S. Clinically used antidepressant drugs. Pharmacopsychiatry. 30(Suppl. 2):1997;71.
14. Müller W.E., Rolli M., Schäfer C., Hafner U. Effects of hypericum extract (LI160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 30(Suppl. 2):1997;102-107.
15. Perovic S., Müller W.E. Pharmacological profile of Hypericum extracts. Effect on serotonin uptake by postsynaptic receptors. Arneimitterforschung Drug Research. 45:1995;1145-1148.
16. Neary J.T., Bu Y. Hypericum LI160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Research. 816:1999;358-363.
17. Calapai G., Crupi A., Firenzuoli F., Constantino G., Inferrerea G., Campo G.H., Caputi A.P. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. Journal of Pharmacy and Pharmacology. 51:1999;723-728.
18. Kaehler S.T., Sinner C., Chatterjee S.S., Philippu A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate on the rat locus coeruleus. Neuroscience Letters. 262:1999;199-202.
19. 2A receptors. Pharmacopsychiatry. 30(Suppl. 2):1997;113-116.
20. Chatterjee S.S., Bhattacharya S.K., Wonnemann M., Singer A., Müller W.E. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sciences. 63:1998;499-510.
21. 2 extract of St. John's wort (Hypericum perforatum) on intracerebral field potentials in the freely waving rats. Pharmacopsychiatry. 31(Suppl. 1):1998;30-35.
22. Gobbi M., Dalla Velle F., Clapparelli C., Diomede L., Morazzoni P., Verotta L., Caccia S., Cervo L., Mennini T. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn-Schmiedebergs Archives of Pharmacology. 360:1999;262-269.
23. Jensen A.G., Hansen S.H., Nielsen E.O. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sciences. 68:2001;1593-1605.
24. Hoelzl J., Ostrowski E. Johanniskraut (Hypericum perforatum). Deutsche Apotheker Zeitung. 46:1987;1227-1230.
25. Lavie G., Valentine F., Levin B., Mazur Y., Gallo G., Lavie D., Weiner D., Meruelo D. Studies of the mechanism of action of the antiretroviral agents hypericin and pseudohypericin. Proceeding of the National Academy of Sciences of the USA. 86:1989;5963-5967.
26. Erdelmeier C.A. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry. 31(Suppl. 1):1998;2-6.
27. Coyle J.T., Snyder S.H. Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. Journal of Pharmacology Experimental Therapeutics. 170:1969;221-231.
28. 3H]desipramine to rat brain: a presynaptic marker for noradrenergic uptake sites. Journal of Neurochemistry. 38:1982;889-895.
29. 2+-ATPase and a pH gradient in the storage of catecholamines in synaptic vesicles. Biochemistry. 17:1978;1523-2517.
30. Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. Journal of Neurochemistry. 47:1986;331-339.
31. 3H]imipramine localization and relationship to serotonin transporter. Journal of Pharmacology and Experimental Therapeutics. 252:1990;410-418.
32. Gordon I., Weizman R., Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. European Journal of Pharmacology. 298:1995;27-30.
33. 3H] Nisoxetine: a new radioligand for norepinephrine uptake sites in brain. European Journal of Pharmacology. 191:1990;239-243.
34. Rehavi M., Goldin M., Roz N., Weizman A. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Molecular of Brain Research. 57:1998;31-37.
35. 3H-GABA by hyperforin, a major constituent of St. John's wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology. 23:2000;188-196.
36. 125I]iodoketanserine. Neuroscience. 33:1980;341-349.
37. 3H]dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum. Neuroscience Letters. 114:1990;45-50.
38. 2+-ATPase and pH gradient in storage of catecholamines in synaptic vesicles. Biochemistry. 17:1978;1523-2517.
39. Chatterjee S.S., Biber A., Weibezahn C. Stimulation of glutamate, aspartate and gamma-aminobutyric acid release from synaptosomes by hyperforin. Pharmacopsychiatry. 34(Suppl. 1):2001;511-519.